| scholarly article | Q13442814 |
| P50 | author | Lars Klareskog | Q5912759 |
| Lucas Settas | Q125311030 | ||
| Saeed Fatenejad | Q125311174 | ||
| Désirée van der Heijde | Q47262835 | ||
| Robert Landewé | Q47264015 | ||
| P2093 | author name string | Vicente Rodríguez-Valverde | |
| Ronald Pedersen | |||
| P2860 | cites work | The course of radiologic damage during the first six years of rheumatoid arthritis. | Q50665522 |
| How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion | Q30688001 | ||
| Radiographic progression depicted by probability plots: presenting data with optimal use of individual values | Q30912433 | ||
| Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 | ||
| Structural damage in rheumatoid arthritis as visualized through radiographs | Q34731299 | ||
| Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis | Q41945874 | ||
| COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention | Q43882911 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 49-60 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study | |
| P478 | volume | 52 |
| Q95359352 | Q95359352 |
| Q36759817 | A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. |
| Q37546519 | A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis |
| Q82887715 | Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis |
| Q36823684 | Combination therapy for rheumatoid arthritis in the era of biologicals |
| Q81658198 | Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial |
| Q36780936 | Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? |
| Q41929910 | Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial |
| Q84564364 | Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission |
| Q40705952 | Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). |
| Q24202751 | Etanercept for the treatment of rheumatoid arthritis |
| Q53124125 | Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis. |
| Q33614786 | Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad |
| Q51676891 | Impact of sex, age, body mass index and handedness on finger joint space width in patients with prolonged rheumatoid arthritis using computer-aided joint space analysis. |
| Q80167144 | In-office imaging in the care of patients with rheumatoid arthritis |
| Q39863736 | Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis |
| Q34607794 | Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension |
| Q46225217 | MTRR A66G, RFC1 G80A, and MTHFR C677T and A1298C Polymorphisms and Disease Activity in Mexicans with Rheumatoid Arthritis Treated with Methotrexate |
| Q30679899 | Missing radiographic data handling in randomized clinical trials in rheumatoid arthritis |
| Q85950374 | Performance of computer-based analysis using temporal subtraction to assess joint space narrowing progression in rheumatoid patients |
| Q44566796 | Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept |
| Q52965383 | Predictive factors related to shoulder joint destruction in rheumatoid arthritis patients treated with biologics: A prospective study. |
| Q31012453 | Presentation and analysis of radiographic data in clinical trials and observational studies |
| Q36749778 | Primer: Demystifying risk--understanding and communicating medical risks |
| Q36577498 | Primer: assessing the efficacy and safety of nonpharmacologic treatments for chronic rheumatic diseases |
| Q36984889 | Primer: challenges in randomized and observational studies |
| Q52650418 | Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. |
| Q90502051 | Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 |
| Q49218023 | Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial |
| Q30571393 | Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis. |
| Q58761666 | The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis |
| Q34462557 | Treating rheumatoid arthritis to target: recommendations of an international task force |
| Q30760660 | Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla |
| Q52895477 | [Therapeutic strategies in rheumatoid arthritis]. |
Search more.